UDCA treatment against COVID-19: Do we have enough clinical evidence for drug repurposing?
J Intern Med
.
2024 Jan;295(1):110-112.
doi: 10.1111/joim.13711.
Epub 2023 Aug 22.
Authors
Luisa Ojeda-Fernández
1
,
Marta Baviera
1
,
Giulia Macaluso
1
,
Simone Schena
1
,
Mauro Tettamanti
1
,
Massimo Cartabia
1
,
Andreana Foresta
1
,
Pier Manuccio Manucci
2
,
Alessandro Nobili
1
,
Giuseppe Remuzzi
1
,
Carla Roncaglioni
1
Affiliations
1
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
2
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and University of Milan, Milan, Italy.
PMID:
37592407
DOI:
10.1111/joim.13711
No abstract available
Publication types
Letter
Comment
MeSH terms
Antiviral Agents / therapeutic use
COVID-19*
Drug Repositioning
Humans
SARS-CoV-2
Substances
Antiviral Agents